{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:47:48Z","timestamp":1787021268653,"version":"build-2736575974"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T00:00:00Z","timestamp":1469664000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1208\/s12249-016-0589-9","type":"journal-article","created":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T12:29:56Z","timestamp":1469708996000},"page":"1228-1241","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Potential Use of Cyclodextrin Complexes for Enhanced Stability, Anti-inflammatory Efficacy, and Ocular Bioavailability of Loteprednol Etabonate"],"prefix":"10.1208","volume":"18","author":[{"given":"Osama Abd El-Aazeem","family":"Soliman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham Abdel Monem","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa Salah","family":"El-Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil Abdullah Ali","family":"Khatera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,28]]},"reference":[{"key":"589_CR1","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1208\/aapsj070479","volume":"7","author":"N Bodor","year":"2005","unstructured":"Bodor N, Buchwald P. Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J. 2005;7:820\u201333.","journal-title":"AAPS J"},{"key":"589_CR2","unstructured":"Bodor NS. Soft steroids having anti-inflammatory activity. US patent No. 4996335 A, 1991."},{"key":"589_CR3","unstructured":"Bartels SP. Use of loteprednol etabonate for the treatment of dry eye. European patent No. EP 2 127 655 A1, 2009."},{"key":"589_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.steroids.2011.01.006","volume":"76","author":"P Chowdhury","year":"2011","unstructured":"Chowdhury P, Borah JM, Goswami P, Das AM. A convenient synthesis of the side chain of loteprednol etabonate\u2014an ocular soft corticosteroid from 20-oxopregnanes using metal-mediated halogenation as a key reaction. Steroids. 2011;76:497\u2013501.","journal-title":"Steroids"},{"key":"589_CR5","first-page":"178","volume":"55","author":"JF Howes","year":"2000","unstructured":"Howes JF. Loteprednol etabonate: a review of ophthalmic clinical studies. Pharmazie. 2000;55:178\u201383.","journal-title":"Pharmazie"},{"key":"589_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.steroids.2003.09.010","volume":"69","author":"Y Shirasaki","year":"2004","unstructured":"Shirasaki Y, Inada K, Inoue J, Nakamura M. Isolation and structure elucidation of the major photodegradation products of loteprednol etabonate. Steroids. 2004;69:23\u201334.","journal-title":"Steroids"},{"key":"589_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/01.ICL.0000092071.82938.46","volume":"30","author":"H Ilyas","year":"2004","unstructured":"Ilyas H, Slonim CB, Braswell GR, Favetta JR, Schulman M. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens. 2004;30:10\u20133.","journal-title":"Eye Contact Lens"},{"key":"589_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ajo.2004.04.052","volume":"138","author":"SC Pflugfelder","year":"2004","unstructured":"Pflugfelder SC, Maskin SL, Anderson B, Chodosh J, Holland EJ, De Paiva CS, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138:444\u201357.","journal-title":"Am J Ophthalmol"},{"key":"589_CR9","first-page":"65","volume":"6","author":"R Dubey","year":"2006","unstructured":"Dubey R. Pure drug nanosuspension: impact of nanotechnology on drug discovery and development. Drug Deliv Technol. 2006;6:65\u201371.","journal-title":"Drug Deliv Technol"},{"key":"589_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0960-0760(91)90120-T","volume":"38","author":"P Druzgala","year":"1991","unstructured":"Druzgala P, Hochhaus G, Bodor N. Soft drugs\u201410. Blanching activity and receptor binding affinity of a new type of glucocorticoid. Loteprednol etabonate. J Steroid Biochem Mol Biol. 1991;38:149\u201354.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"589_CR11","first-page":"206","volume":"55","author":"N Bodor","year":"2000","unstructured":"Bodor N, Drustrup J, Wu W. Effect of cyclodextrins on the solubility and stability of a novel soft corticosteroid, loteprednol etabonate. Pharmazie. 2000;55:206\u20139.","journal-title":"Pharmazie"},{"key":"589_CR12","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1021\/js950534b","volume":"85","author":"T Loftsson","year":"1996","unstructured":"Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci. 1996;85:1017\u201325.","journal-title":"J Pharm Sci"},{"key":"589_CR13","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1021\/js960075u","volume":"85","author":"RA Rajewski","year":"1996","unstructured":"Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins, 2. In-vivo drug delivery. J Pharm Sci. 1996;85:1017\u201325.","journal-title":"J Pharm Sci"},{"key":"589_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2165\/00137696-200402040-00006","volume":"2","author":"T Loftsson","year":"2004","unstructured":"Loftsson T, Brewster ME, Masson M. Role of cyclodextrins in improving oral drug delivery. Am J Drug Deliv. 2004;2:261\u201375.","journal-title":"Am J Drug Deliv"},{"key":"589_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0169-409X(98)00055-6","volume":"36","author":"T Loftsson","year":"1999","unstructured":"Loftsson T, Jarvinen T. Cyclodextrins in ophthalmic drug delivery. Adv Drug Deliv Rev. 1999;36:59\u201379.","journal-title":"Adv Drug Deliv Rev"},{"key":"589_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0378-5173(01)00761-X","volume":"225","author":"T Loftsson","year":"2001","unstructured":"Loftsson T, Masson M. Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm. 2001;225:15\u201330.","journal-title":"Int J Pharm"},{"key":"589_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1034\/j.1600-0420.2002.800205.x","volume":"80","author":"T Loftsson","year":"2002","unstructured":"Loftsson T, Stef\u00e1nsson E. Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye. Acta Ophthalmol Scand. 2002;80:144\u201350.","journal-title":"Acta Ophthalmol Scand"},{"key":"589_CR18","first-page":"51","volume-title":"Ocular therapeutics and drug delivery. A multidisciplinary approach","author":"JC Lang","year":"1996","unstructured":"Lang JC, Stiemke MM. Biological barriers to ocular delivery. In: Reddy IK, editor. Ocular therapeutics and drug delivery. A multidisciplinary approach. Lancaster: Technomic; 1996. p. 51\u2013132."},{"key":"589_CR19","unstructured":"European Medicine Agency. Background review for cyclodextrins used as excipients. EMA\/CHMP\/333892\/2013."},{"key":"589_CR20","doi-asserted-by":"crossref","unstructured":"Washington N, Washington C, Wilson CG. Ocular drug delivery. In: Physiological pharmaceutics. USA: Taylor and Francis Inc; 2001. p. 249\u2013270.","DOI":"10.1201\/9780203483701"},{"key":"589_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0378-5173(00)00359-8","volume":"199","author":"IP Kaur","year":"2000","unstructured":"Kaur IP, Singh M, Kanwar M. Formulation and evaluation of ophthalmic preparations of acetazolamide. Int J Pharm. 2000;199:119\u201327.","journal-title":"Int J Pharm"},{"key":"589_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1089\/jop.1996.12.159","volume":"12","author":"IK Reddy","year":"1996","unstructured":"Reddy IK, Khan MA, Wu WM, Bodor NS. Permeability of a soft steroid, loteprednol etabonate, through an excised rabbit cornea. J Ocul Pharmacol Ther. 1996;12:159\u201367.","journal-title":"J Ocul Pharmacol Ther"},{"key":"589_CR23","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1208\/s12249-008-9042-z","volume":"9","author":"MM Doile","year":"2008","unstructured":"Doile MM, Fortunato KA, Schm\u00fccker IC, Schucko SK, Silva MA, Rodrigues PO. Physicochemical properties and dissolution studies of dexamethasone acetate-\u03b2-cyclodextrin inclusion complexes produced by different methods. AAPS PharmSciTech. 2008;9:314\u201321.","journal-title":"AAPS PharmSciTech"},{"key":"589_CR24","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1208\/s12249-008-9143-8","volume":"9","author":"A Ribeiro","year":"2008","unstructured":"Ribeiro A, Figueiras A, Santos D, Veiga F. Preparation and solid-state characterization of inclusion complexes formed between miconazole and methyl-\u03b2-cyclodextrin. AAPS PharmSciTech. 2008;9:1102\u20139.","journal-title":"AAPS PharmSciTech"},{"key":"589_CR25","first-page":"459","volume":"7","author":"T Jansen","year":"1990","unstructured":"Jansen T, Xhonneux B, Mesens J, Borgers M. Beta-cyclodextrins as vehicles in eye-drop formulation: an evaluation of their effects on rabbit corneal epithelium. Lens Eye Toxic Res. 1990;7:459\u201368.","journal-title":"Lens Eye Toxic Res"},{"key":"589_CR26","first-page":"3150","volume":"21","author":"A Kanai","year":"1989","unstructured":"Kanai A, Alba RM, Takano T, Kobayashi C, Nakajima A, Kurihara K, et al. The effect on the cornea of alpha cyclodextrin vehicle for cyclosporine eye drops. Transplant Proc. 1989;21:3150\u20132.","journal-title":"Transplant Proc"},{"key":"589_CR27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3109\/03639049709148496","volume":"23","author":"E Loftsson","year":"1997","unstructured":"Loftsson E, Stefansson E. Effect of cyclodextrin on topical drug delivery to the eye. Drug Dev Ind Pharm. 1997;23:473\u201381.","journal-title":"Drug Dev Ind Pharm"},{"key":"589_CR28","unstructured":"Javitt JC, Javitt NB, McDonnell P. Topical compositions for the eye comprising a beta-cyclodextrin derivative and a carbonic anhydrase inhibitor, International patent application No. WO 94\/15582, 1994."},{"key":"589_CR29","first-page":"277","volume":"6","author":"T Loftsson","year":"1996","unstructured":"Loftsson T, Stefansson E, Kristinsson JK, Fridriksdottir H, Sverrisson T, Gudmundsdottir G, et al. Topically effective acetazolamide eye-drop solution in man. Pharm Sci. 1996;6:277\u20139.","journal-title":"Pharm Sci"},{"key":"589_CR30","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1023\/A:1011956327987","volume":"15","author":"P Saarinen-Savolainen","year":"1998","unstructured":"Saarinen-Savolainen P, J\u00e4rvinen T, Araki-Sasaki K, Watanabe H, Urtti A. Evaluation of cytotoxicity of various drugs, eye drop excipients and cyclodextrins in immortalized human corneal epithelial cell line. Pharm Res. 1998;15:1275\u201380.","journal-title":"Pharm Res"},{"key":"589_CR31","first-page":"117","volume":"4","author":"T Higuchi","year":"1965","unstructured":"Higuchi T, Connors KA. Phase solubility techniques. Adv Anal Chem Instrum. 1965;4:117\u201322.","journal-title":"Adv Anal Chem Instrum"},{"key":"589_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ijpharm.2005.05.042","volume":"302","author":"T Loftsson","year":"2005","unstructured":"Loftsson T, Hreinsdottir D, Masson M. Evaluation of cyclodextrin solubilization of drugs. Int J Pharm. 2005;302:18\u201328.","journal-title":"Int J Pharm"},{"key":"589_CR33","first-page":"101","volume-title":"Modern pharmaceutics","author":"PJ Missel","year":"2009","unstructured":"Missel PJ, Lang JC, Rodeheaver DP, Jani R, Chowhan MA, Chastain J, et al. Design and evaluation of ophthalmic pharmaceutical products. In: Florence AT, Siepmann J, editors. Modern pharmaceutics. New York: Informa Healthcare; 2009. p. 101\u201389."},{"key":"589_CR34","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3109\/02713680903340738","volume":"34","author":"RM Gilhotra","year":"2009","unstructured":"Gilhotra RM, Gilhotra N, Mishra DN. Piroxicam bioadhesive ocular inserts: physicochemical characterization and evaluation in prostaglandin-induced inflammation. Curr Eye Res. 2009;34:1065\u201373.","journal-title":"Curr Eye Res"},{"key":"589_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4103\/2230-973X.76725","volume":"1","author":"RM Gilhotra","year":"2011","unstructured":"Gilhotra RM, Nagpal K, Mishra DN. Azithromycin novel drug delivery system for ocular application. Int J Pharm Investig. 2011;1:22\u20138.","journal-title":"Int J Pharm Investig"},{"key":"589_CR36","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1023\/A:1015813225804","volume":"8","author":"NM Davies","year":"1991","unstructured":"Davies NM, Farr SJ, Hadgraft J, Kellaway IW. Evaluation of mucoadhesive polymers in ocular drug delivery, I. Viscous solutions. Pharm Res. 1991;8:1039\u201343.","journal-title":"Pharm Res"},{"key":"589_CR37","first-page":"124","volume":"41","author":"FS Habib","year":"1986","unstructured":"Habib FS, Attia MA, El-Shanawany SM. In-vitro study of physostigmine salicylate and pilocarpine hydrochloride release from different gel formulations. Pharmazie. 1986;41:124\u20135.","journal-title":"Pharmazie"},{"key":"589_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0378-5173(90)90381-D","volume":"66","author":"MY Levy","year":"1990","unstructured":"Levy MY, Benita S. Drug release from submicronized o\/w emulsion: new in-vitro kinetic evaluation model. Int J Pharm. 1990;66:29\u201337.","journal-title":"Int J Pharm"},{"key":"589_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0378-5173(01)00895-X","volume":"232","author":"T Loftsson","year":"2002","unstructured":"Loftsson T, Masson M, Sigurdsson HH. Cyclodextrins and drug permeability through semipermeable cellophane membranes. Int J Pharm. 2002;232:35\u201343.","journal-title":"Int J Pharm"},{"key":"589_CR40","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.ijpharm.2012.11.002","volume":"441","author":"MD Moya-Ortega","year":"2013","unstructured":"Moya-Ortega MD, Alves TF, Alvarez-Lorenzo C, Concheiro A, Stef\u00e1nsson E, Thorsteinsd\u00f3ttir M, et al. Dexamethazone eye drops containing \u03b3-cyclodextrin-based nanogels. Int J Pharm. 2013;441:507\u201315.","journal-title":"Int J Pharm"},{"key":"589_CR41","unstructured":"Martin A, Bustamante P, Chun AHC. Kinetics. In: Physical pharmacy. Philadelphia: Lea and Febiger; 1993. p. 284\u2013323."},{"key":"589_CR42","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/jps.2600521210","volume":"52","author":"T Higuchi","year":"1963","unstructured":"Higuchi T. Mechanism of sustained action medication. J Pharm Sci. 1963;52:1145\u20139.","journal-title":"J Pharm Sci"},{"key":"589_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0168-3659(87)90034-4","volume":"5","author":"PL Ritger","year":"1987","unstructured":"Ritger PL, Peppas NA. Simple equation for description of solute release: part 1, Fickian and non-Fickian release from nonswellable devices in the form of slab, spheres, cylinders or disk. J Control Release. 1987;5:23\u201336.","journal-title":"J Control Release"},{"key":"589_CR44","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2307\/1931961","volume":"41","author":"PW Winston","year":"1960","unstructured":"Winston PW, Bates DH. Saturated solutions for the control of humidity in biological research. Ecology. 1960;41:232\u20137.","journal-title":"Ecology"},{"key":"589_CR45","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/jps.3030440817","volume":"44","author":"ER Garrett","year":"1955","unstructured":"Garrett ER, Carper RF. Prediction of stability in pharmaceutical preparations I. Color stability in a liquid multisulfa preparation. J Am Pharm Assoc. 1955;44:515\u20138.","journal-title":"J Am Pharm Assoc"},{"key":"589_CR46","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/clinchem\/37.3.398","volume":"37","author":"G Anderson","year":"1991","unstructured":"Anderson G, Scott M. Determination of product shelf life and activation energy for five drugs of abuse. Clin Chem. 1991;37:398\u2013402.","journal-title":"Clin Chem"},{"key":"589_CR47","unstructured":"Lund W. Ophthalmic products. In: The pharmaceutical codex. London: The Pharmaceutical Press; 1994. p. 160\u2013169."},{"key":"589_CR48","first-page":"252","volume":"2","author":"V Saxena","year":"2013","unstructured":"Saxena V, Singh A. Development and validation of HPLC method for the simultaneous estimation of loteprednol and gatifloxacin. IJSR. 2013;2:252\u20135.","journal-title":"IJSR"},{"key":"589_CR49","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1167\/iovs.07-0214","volume":"49","author":"NP Cheruvu","year":"2008","unstructured":"Cheruvu NP, Amrite AC, Kompella UB. Effect of eye pigmentation on transscleral drug delivery. Invest Ophthalmol Vis Sci. 2008;49:333\u201341.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"589_CR50","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1248\/cpb.37.1059","volume":"37","author":"A Yoshida","year":"1989","unstructured":"Yoshida A, Yamamoto M, Irie T, Hirayama F, Uekama K. Some pharmaceutical properties of 3-hydroxypropyl- and 2,3-dihydroxypropyl-beta-cyclodextrins and their solubilizing and stabilizing abilities. Chem Pharm Bull. 1989;37:1059\u201363.","journal-title":"Chem Pharm Bull"},{"key":"589_CR51","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ejmech.2007.03.037","volume":"43","author":"GE Granero","year":"2008","unstructured":"Granero GE, Maitre MM, Garnero C, Longhi MR. Synthesis, characterization and in vitro release studies of a new acetazolamide-HP-F-CD-TEA inclusion complex. Eur J Med Chem. 2008;43:464\u201370.","journal-title":"Eur J Med Chem"},{"key":"589_CR52","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1248\/cpb.60.736","volume":"60","author":"J Su","year":"2012","unstructured":"Su J, Chen J, Li L, Li B, Shi L, Zhang H, et al. Preparation of natural borneol\/2-hydroxypropyl-\u03b2-cyclodextrin inclusion complex and its effect on the absorption of tetramethylpyrazine phosphate in mouse. Chem Pharm Bull. 2012;60:736\u201342.","journal-title":"Chem Pharm Bull"},{"key":"589_CR53","doi-asserted-by":"publisher","first-page":"14251","DOI":"10.3390\/ijms131114251","volume":"13","author":"L Cui","year":"2012","unstructured":"Cui L, Zhang ZH, Sun E, Jia XB. Effect of \u03b2-cyclodextrin complexation on solubility and enzymatic conversion of naringin. Int J Mol Sci. 2012;13:14251\u201361.","journal-title":"Int J Mol Sci"},{"key":"589_CR54","unstructured":"B. P. British pharmacopeia, Vol. III, 6th Ed. London: The Council of Europe, The Stationary Office; 2010. p. 3155\u20133157."},{"key":"589_CR55","unstructured":"Amselem SR, Friedman D, Yosef C. Suspension of loteprednol etabonate for ear, eye, or nose treatment. US Patent # 5747061. 1998."},{"key":"589_CR56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1208\/pt070238","volume":"7","author":"E Bilensoy","year":"2006","unstructured":"Bilensoy E, Rouf MA, Vural I, Sen M, Hincal AA. Mucoadhesive, thermosensitive, prolonged-release vaginal gel for clotrimazole: \u03b2-cyclodextrin complex. AAPS PharmSciTech. 2006;7:38\u201344.","journal-title":"AAPS PharmSciTech"},{"key":"589_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/pt0804100","volume":"8","author":"H Abdelkader","year":"2007","unstructured":"Abdelkader H, Abdallah OY, Salem HS. Comparison of the effect of tromethamine and polyvinylpyrrolidone on dissolution properties and analgesic effect of nimesulide. AAPS PharmSciTech. 2007;8:1\u20138.","journal-title":"AAPS PharmSciTech"},{"key":"589_CR58","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1208\/s12249-012-9812-5","volume":"13","author":"EA Mohamed","year":"2012","unstructured":"Mohamed EA, Meshali MM, Foda AM, Borg TM. Improvement of dissolution and hypoglycemic efficacy of glimepiride by different carriers. AAPS PharmSciTech. 2012;13:1013\u201323.","journal-title":"AAPS PharmSciTech"},{"key":"589_CR59","doi-asserted-by":"publisher","first-page":"208","DOI":"10.5714\/CL.2009.10.3.208","volume":"10","author":"A Oh","year":"2009","unstructured":"Oh A, Jin DH, Yun J, Lee YS, Kim H. Effect of pH-dependent solubility on release behavior of alginate-chitosan blend containing activated carbon. Carbon Lett. 2009;10:208\u201312.","journal-title":"Carbon Lett"},{"key":"589_CR60","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.3109\/03639049409042648","volume":"20","author":"MJ Durrani","year":"1994","unstructured":"Durrani MJ, Andrews A, Whitaker R, Benner SC. Studies on drug release kinetics from carbomer matrices. Drug Dev Ind Pharm. 1994;20:2439\u201347.","journal-title":"Drug Dev Ind Pharm"},{"key":"589_CR61","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0378-5173(96)04441-9","volume":"135","author":"M Zhou","year":"1996","unstructured":"Zhou M, Donovan MD. Intranasal mucociliary clearance of putative bioadhesive polymer gels. Int J Pharm. 1996;135:115\u201325.","journal-title":"Int J Pharm"},{"key":"589_CR62","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ijpharm.2007.04.013","volume":"343","author":"L Budai","year":"2007","unstructured":"Budai L, Hajdu M, Budai M, Grof P, Beni S, Noszal B, et al. Gels and liposomes in optimized ocular drug delivery: studies on ciprofloxacin formulations. Int J Pharm. 2007;343:34\u201340.","journal-title":"Int J Pharm"},{"key":"589_CR63","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1208\/s12249-011-9701-3","volume":"12","author":"MH Aburahma","year":"2011","unstructured":"Aburahma MH, Mahmoud AA. Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro\/in vivo evaluation. AAPS PharmSciTech. 2011;12:1335\u201347.","journal-title":"AAPS PharmSciTech"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-016-0589-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12249-016-0589-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-016-0589-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-016-0589-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T09:05:20Z","timestamp":1600938320000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12249-016-0589-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,28]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["589"],"URL":"https:\/\/doi.org\/10.1208\/s12249-016-0589-9","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,28]]}}}